Cite
HARVARD Citation
Brenner, A. et al. (n.d.). 2901 Phase 2 study of VB-, an anti-cancer gene therapy, as monotherapy followed by combination of VB-111 with bevacizumab, in patients with recurrent glioblastoma. European journal of cancer. pp. S584-. [Online].